Document is current
Any future updates will be listed below
-
Authors
Spurgeon, Laura https://orcid.org/0000-0003-4152-5068
Mitchell, Claire
Cook, Natalie https://orcid.org/0000-0003-2606-1082
Conway, Alicia-Marie https://orcid.org/0000-0003-2635-8206
- License Information
-
More Information
Article History
Received: 13 March 2025
Revised: 1 May 2025
Accepted: 20 May 2025
First Online: 4 July 2025
Competing interests
: NC has received consulting fees from Roche Pharmaceuticals, Servier and REDX Pharmaceuticals; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Pharmaceuticals; support for attending meetings and/or travel from Roche Pharmaceuticals; research funding to research team from AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck and Tarveda Therapeutics; participated in data safety monitoring board or advisory board at Roche Pharmaceuticals and Cancer Research UK. AMC has received support for attending meetings and/or travel from Roche Products Limited, and is a named inventor on a patent registered by “Cancer Research Technology Ltd”. LS and CM declare no potential competing interests.
